Cargando…

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment

Background and Objectives: To find the differences in ocular axial length, keratometric measurements, and intraocular lens (IOL) power in patients with Graves’ disease (GD) after treatment with a thionamide antithyroid drug (ATD), methimazole. Materials and Methods: The medical charts of 28 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Je-Sang, Yeom, Dong-Ju, Nah, Seung-Kwan, Kim, Bo-Yeon, Jang, Sun-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146600/ https://www.ncbi.nlm.nih.gov/pubmed/33922887 http://dx.doi.org/10.3390/medicina57050414

Ejemplares similares

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
por: Choi, Yun Mi, et al.
Publicado: (2019)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
por: Jin, Meihua, et al.
Publicado: (2023)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid drugs
por: Jastrzębska, Helena
Publicado: (2015)

Antithyroid Drugs
por: Abdi, Hengameh, et al.
Publicado: (2019)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment
por: Fukao, Atsushi, et al.
Publicado: (2011)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
por: Liu, Xiaomei, et al.
Publicado: (2015)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study
por: Karmisholt, J., et al.
Publicado: (2019)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Long-Term Antithyroid Drug Treatment of Graves’ Disease in Children and Adolescents: A 20-Year Single-Center Experience
por: Song, Ari, et al.
Publicado: (2021)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study
por: Kurozumi, Akira, et al.
Publicado: (2022)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
por: Kim, Hyunsam, et al.
Publicado: (2018)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report
por: Yan, Lily D., et al.
Publicado: (2017)

MON-621 A Second Course of Antithyroid Drug Therapy Is Effective in Patients with Relapsed Graves' Disease
por: Seejore, Khyatisha, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves’ Disease in Ethiopia
por: Mengistu, Habtamu Solomon, et al.
Publicado: (2022)

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease
por: Gill, Harinder, et al.
Publicado: (2010)

Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
por: Yotsapon, Thewjitcharoen, et al.
Publicado: (2022)

Toxic Effects of Antithyroid Drugs
por: Peters, J. P., et al.
Publicado: (1949)

Antithyroid drugs and birth defects
por: Andersen, Stine Linding, et al.
Publicado: (2020)

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation
por: Subramanian, Muthiah, et al.
Publicado: (2016)

MON-589 Prognostic Predictors of Initial Response of Graves' Disease to Antithyroid Drugs: A Single Center Experience
por: Alaghoury, Aliaa, et al.
Publicado: (2019)

Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs
por: Cheng, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_njs1b5f3no2rkpu2bke765dtdc